AZPIL Archives - The Pharma Times | Pharma & Health Care News Portal

Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
AZPIL Archives - The Pharma Times | Pharma & Health Care News Portal

AZPIL

AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India

Durvalumabis the only immunotherapy approved for patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Durvalumabwas granted US FDA…

6 years ago